透析液钠与血浆钠对全球血透队列死亡率的影响
该回顾性队列纳入25国875家中心的68,196例新发血透患者,评估透析液钠(≤138 vs >138 mmol/L)与全因死亡的关系。中位随访40个月,21,644例死亡;透析液钠≤138 mmol/L与更高的死亡风险独立相关(多变量HR 1.57,95%CI 1.25–1.98),且不受血浆钠水平影响。
要点
- 透析液钠≤138 mmol/L与更高的全因死亡风险独立相关(HR 1.57,95%CI 1.25–1.98)。
- 无论血浆钠水平如何,暴露于较高透析液钠(>138 mmol/L)的患者死亡风险更低。
- 亚组分析未发现血浆钠或其他患者特征对上述关联有效应修饰证据。
核心结论
- 透析液钠≤138 mmol/L与更高的全因死亡风险独立相关(多变量HR 1.57,95%CI 1.25–1.98),且不受血浆钠水平影响。
- 该观察性结果挑战了较低透析液钠改善血透患者结局的假设,需随机试验证据确定最佳透析液钠处方。
研究设计与样本
- 回顾性队列研究,纳入2010–2019年25国875家Fresenius Medical Care Nephrocare诊所的68,196例新发血透患者。
- 基线透析液钠(≤138或>138 mmol/L)和血浆钠(<135、135–142、>142 mmol/L)定义暴露状态。
- 采用按国家分层的多变量Cox回归模型分析时变透析液和血浆钠暴露与全因死亡的关系,校正人口学和治疗变量(包括生物电阻抗测量的液体状态)。
主要发现
- 透析液钠138 mmol/L处方的患者占63.2%,139 mmol/L占15.8%,140 mmol/L占20.7%,其他浓度占0.4%;78.6%的中心使用标准化浓度。
- 中位随访40个月期间,21,644例(约三分之一)患者死亡。
- 透析液钠≤138 mmol/L与更高的全因死亡风险相关(多变量HR 1.57,95%CI 1.25–1.98),已校正血浆钠和其他混杂变量。
- 亚组分析未显示血浆钠浓度或其他患者特定变量对上述关联有效应修饰证据。
临床怎么用
- 研究结果提示,在随机试验证据可用之前,肾内科医生重新考虑透析液钠处方实践时应保持谨慎,以优化心血管结局并降低该人群死亡率。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SIGNIFICANCE STATEMENT: This large observational cohort study aimed to investigate the relationship between dialysate and plasma sodium concentrations and mortality among maintenance hemodialysis patients. Using a large multinational cohort of 68,196 patients, we found that lower dialysate sodium concentrations (≤138 mmol/L) were independently associated with higher mortality compared with higher dialysate sodium concentrations (>138 mmol/L). The risk of death was lower among patients exposed to higher dialysate sodium concentrations, regardless of plasma sodium levels. These results challenge the prevailing assumption that lower dialysate sodium concentrations improve outcomes in hemodialysis patients. The study confirms that until robust evidence from randomized trials that are underway is available, nephrologists should remain cautious in reconsideration of dialysate sodium prescribing practices to optimize cardiovascular outcomes and reduce mortality in this population. BACKGROUND: Excess mortality in hemodialysis (HD) patients is largely due to cardiovascular disease and is associated with abnormal fluid status and plasma sodium concentrations. Ultrafiltration facilitates the removal of fluid and sodium, whereas diffusive exchange of sodium plays a pivotal role in sodium removal and tonicity adjustment. Lower dialysate sodium may increase sodium removal at the expense of hypotonicity, reduced blood volume refilling, and intradialytic hypotension risk. Higher dialysate sodium preserves blood volume and hemodynamic stability but reduces sodium removal. In this retrospective cohort, we aimed to assess whether prescribing a dialysate sodium ≤138 mmol/L has an effect on survival outcomes compared with dialysate sodium >138 mmol/L after adjusting for plasma sodium concentration. METHODS: The study population included incident HD patients from 875 Fresenius Medical Care Nephrocare clinics in 25 countries between 2010 and 2019. Baseline dialysate sodium (≤138 or >138 mmol/L) and plasma sodium (<135, 135-142, >142 mmol/L) concentrations defined exposure status. We used multivariable Cox regression model stratified by country to model the association between time-varying dialysate and plasma sodium exposure and all-cause mortality, adjusted for demographic and treatment variables, including bioimpedance measures of fluid status. RESULTS: In 2,123,957 patient-months from 68,196 incident HD patients with on average three HD sessions per week dialysate sodium of 138 mmol/L was prescribed in 63.2%, 139 mmol/L in 15.8%, 140 mmol/L in 20.7%, and other concentrations in 0.4% of patients. Most clinical centers (78.6%) used a standardized concentration. During a median follow-up of 40 months, one third of patients ( n =21,644) died. Dialysate sodium ≤138 mmol/L was associated with higher mortality (multivariate hazard ratio for the total population (1.57, 95% confidence interval, 1.25 to 1.98), adjusted for plasma sodium concentrations and other confounding variables. Subgroup analysis did not show any evidence of effect modification by plasma sodium concentrations or other patient-specific variables. CONCLUSIONS: These observational findings stress the need for randomized evidence to reliably define optimal standard dialysate sodium prescribing practices.
引用
- Pinter J, Smyth B, Stuard S, et al. Effect of Dialysate and Plasma Sodium on Mortality in a Global Historical Hemodialysis Cohort. J Am Soc Nephrol. 2023. PMID: 37967469. doi:10.1681/ASN.0000000000000262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。